In what medical experts are calling a “foundational shift” in the future of cancer treatment, the world’s first therapeutic cancer vaccine has slashed the risk of tumor recurrence by an astonishing 42% in a global phase 3 clinical trial.
The long-awaited results of Moderna’s personalised mRNA vaccine study were unveiled by chief investigator Professor Georgina Long at the European Society of Medical Oncology’s annual Congress in Madrid. Describing the milestone as a new frontier in immunotherapy, Professor Long believes the breakthrough will dramatically improve survival rates for a wide range of malignancies—including many with historically poor prognoses.
Comparing the monumental achievement to aviation history, Professor Long told The Australian, “This is like the first flight. It will have such a significant impact, not just for melanoma patients, but potentially all of cancer.”
As researchers officially present the data to the global scientific community this weekend, this milestone marks the beginning of a transformative era in modern medicine, offering renewed hope to patients and clinicians worldwide.
